Rationale for the combination of venetoclax and ibrutinib in T-prolymphocytic leukemia
Open Access
- 1 August 2021
- journal article
- letter
- Published by Ferrata Storti Foundation (Haematologica) in Haematologica
- Vol. 106 (8), 2251-2256
- https://doi.org/10.3324/haematol.2020.271304
Abstract
No abstract availableThis publication has 15 references indexed in Scilit:
- Consensus criteria for diagnosis, staging, and treatment response assessment of T-cell prolymphocytic leukemiaBlood, 2019
- Biomarker-driven strategy for MCL1 inhibition in T-cell lymphomasBlood, 2019
- EBMT prospective observational study on allogeneic hematopoietic stem cell transplantation in T-prolymphocytic leukemia (T-PLL)Bone Marrow Transplantation, 2019
- Ibrutinib plus Venetoclax for the Treatment of Mantle-Cell LymphomaNew England Journal of Medicine, 2018
- Drug-perturbation-based stratification of blood cancerJCI Insight, 2017
- First-in-human response of BCL-2 inhibitor venetoclax in T-cell prolymphocytic leukemiaBlood, 2017
- Discovery of novel drug sensitivities in T-PLL by high-throughput ex vivo drug testing and mutation profilingLeukemia, 2017
- Genetic characterization of T‐PLL reveals two major biologic subgroups and JAK3 mutations as prognostic markerGenes, Chromosomes and Cancer, 2015
- Interleukin-2-inducible T-cell Kinase (ITK) Targeting by BMS-509744 Does Not Affect Cell Viability in T-cell Prolymphocytic Leukemia (T-PLL)Journal of Biological Chemistry, 2015
- Ibrutinib is an irreversible molecular inhibitor of ITK driving a Th1-selective pressure in T lymphocytesBlood, 2013